BioSpace News Archive

Becomes first insurer to provide LabCorp Home Test-Collection Kits to members, and first to offer drive-thru testing for members at Walmart locations

Bebe Rexha, JoJo, RaeLynn & Ozomatli Perform in Honor of JDRF’s 50th Anniversary and 50 Years of T1D Breakthroughs Hosted by KTLA’s Frank Buckley

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins, announced that it has enrolled its first patients in the NASH-RX trial.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, was added to the US small-cap Russell 2000® Index during the 2020 Russell Indexes reconstitution, effective after the US market close on June 26 th . Membership in the Russell 2000® Index, which remains in place for at least one year, is based on membership in the broad-market

AMRA Medical – global leader in body composition profiling – will collaborate with the National University of Singapore’s (NUS) Yong Loo Lin School of Medicine on an Asian-centric study to enhance the understanding of Non-Alcoholic Fatty Liver Disease (NAFLD).

Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, today announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences, has commenced the collection of convalescent plasma from donors who have recovered from COVID-19.

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO®

Today Immvira Group Company (Immvira or the “Company”), a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, announces the appointment of Carl Yeung as Chief Financial Officer, reporting directly to Dr. Grace Zhou, Chairman and Chief Executive Officer of the Company.

Innovative Medicines Canada released the following statement today in response to the Federal Court of Canada’s decision on its judicial review application regarding the Patented Medicine Prices Review Board amendments to the Patented Medicines Regulations:

Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2020 (“Fiscal 2020").